Global API Market Forecast to 2017
London (PRWEB) September 25, 2013 -- The market for Active Pharmaceutical Ingredients is brimming with activities. While it is consolidating in US and EU resulting in the emergence of few big players producing specialty APIs that target high value markets, new players are entering in the mass markets of India and China. With global healthcare spending to have reached around US$ 6.4 Trillion in 2010 and a rapidly ageing population boosting the demand for pharmaceuticals, APIs represent one of the most exciting markets for growth.
In our latest research study, "Global API Market Forecast to 2017", RNCOS analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 113 Billion in 2012, is expected to grow at a CAGR of around 8% during 2012-2017.
For our study, we have analyzed the global API market from different perspectives. It has been studied at the “Captive vs. Merchant” level; “Branded vs. Generic” level and “Synthetic vs. Biotech level”. This has been done to provide a thorough and apt assessment to players who can use the research findings to support their business strategies.
At the regional level, RNCOS has provided a thorough understanding of the merchant API markets along with their future outlook to 2017. Each region’s market is unique with exports playing a major role in regions of India and China. Each region’s regulatory environment has also been elaborated, while discussing various drivers and challenges, to help new entrants overcome entry barriers. The report also provides a comparative analysis of key regions highlighting labor cost and productivity; price structure with reference to manufacturing indicators of profit margins, raw materials and conversion costs; and investment incurred in plant setups. These research findings will aid international players to strategically expand their presence globally.
RNCOS, while doing the research, thoroughly studied the global revenue patterns of key players. The company’s report covers an overview of all the major players to provide a holistic view of the competitive landscape. Furthermore, the report elaborates on the High Potency API (HPAPI) market dynamics that represents the fastest growing niche. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global API market.
1. Analyst View
2. Research Methodology
3. APIs - An Introduction
4. Industry Performance
4.1 Current and Future Market Analysis to 2017
4.2 Market Segments
4.2.1 Branded and Generic APIs
4.2.2 Synthetic and Biotech APIs
4.3 Future Opportunity Assessment
5. Countries’ Comparative Analysis: API Manufacturing
5.1 Labor Cost and Productivity
5.2 Price Structure
5.3 Investment Cost in Plant Set-up
6. Analysis by Therapeutic Segments
6.1 Central Nervous System Disorders
6.2 Cardiovascular Diseases
6.3 Diabetes
6.4 Respiratory Disorders
6.5 Oncology
7. Key Geographical Markets
7.1 China
7.1.1 Current and Future Market Analysis to 2017
7.1.2 Regional Segmentation
7.1.3 Regulatory Environment
7.1.4 Future Opportunity Assessment
7.2 India
7.2.1 Current and Future Market Analysis to 2017
7.2.2 Regional Segmentation
7.2.3 Regulatory Environment
7.2.4 Future Opportunity Assessment
7.3 Italy
7.3.1 Current and Future Market Analysis to 2017
7.3.2 Regulatory Environment
7.3.3 Future Opportunity Assessment
7.4 Taiwan
8. High-Potency APIs: An Emerging Opportunity
9. Regulatory Environment
10. Competitive Landscape
10.1 Dr Reddy’s Laboratories
10.2 Cipla
10.3 Ranbaxy Laboratories
10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.5 Fabbrica Italiana Sintetici
10.6 Cambrex Corporation
10.7 Pfizer CentreSource
10.8 Teva Active Pharmaceutical Ingredients
10.9 Lonza
10.10 Daiichi Fine Chemicals
10.11 Boehringer Ingelheim GmbH
10.12 BASF SE
10.13 Royal DSM
10.14 Divis Laboratories Limited
10.15 Aurobindo Pharma Limited
List of Figures:
Figure 4-1: Global - API Market (Billion US$), 2012-2017
Figure 4-2: Global - Share of Captive and Merchant Market in API Market (2012)
Figure 4-3: Global - API Captive Market (Billion US$), 2012-2017
Figure 4-4: Global - API Merchant Market (Billion US$), 2012-2017
Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant Market (2012)
Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2012-2017
Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2012-2017
Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market (2012)
Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: China - Pharmaceutical Industry by Segment (2010)
Figure 7-2: China - API Merchant Market (Billion US$), 2012-2017
Figure 7-3: China - Share in Global API Merchant Market (2012)
Figure 7-4: China - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-5: China - Share in Global Generic API Merchant Market (2012)
Figure 7-6: India - API Merchant Market (Billion US$), 2012-2017
Figure 7-7: India - Share in Global API Merchant Market (2012)
Figure 7-8: India - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-9: India - Share in Global Generic API Merchant Market (2012)
Figure 7-10: Italy - API Merchant Market (Billion US$), 2012-2017
Figure 7-11: Italy - Share in Global API Merchant Market (2012)
Figure 7-12: Italy - Number of API Producers and Manufacturing Plants (1991, 2000 & 2009)
Figure 7-13: Italy - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-14: Italy - Share in Global Generic API Merchant Market (2012)
Figure 7-15: Taiwan - API Market (Billion NT$), 2010 & 2011
Figure 8-1: Global - HPAPI Market (Billion US$), 2012-2017
Figure 8-2: Global - Share of Synthetic and Biotech HPAPIs in HPAPI Market (2012)
Figure 8-3: Global - Share of Generics and Branded in HPAPI Market (2012)
List of Tables:
Table 3-1: Classification of Bulk Drugs
Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global - Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 7-1: China - Number of API Companies by Province
Table 7-2: India - Number of Bulk Drugs Manufacturing Units
Table 7-3: Taiwan - Number of Pharmaceutical Licenses by Type (2010)
Table 9-1: Scope of Authority for Regulatory Agencies
Table 10-1: Dr. Reddy's Laboratories - Strengths and Weaknesses
Table 10-2: Cipla - Strengths and Weaknesses
Table 10-3: Ranbaxy Laboratories - Strengths and Weaknesses
Table 10-4: Zhejiang Hisun Pharmaceutical - Strengths and Weaknesses
Table 10-5: Fabbrica Italiana Sintetici - Strengths and Weaknesses
Table 10-6: Cambrex Corporation - Strengths and Weaknesses
Table 10-7: Pfizer CentreSource - Strengths and Weaknesses
Table 10-8: Teva Active Pharmaceutical Ingredients - Strengths and Weaknesses
Table 10-9: Lonza - Strengths and Weaknesses
Table 10-10: Daiichi Fine Chemical - Strengths and Weaknesses
Table 10-11: Boehringer Ingelheim - Strengths and Weaknesses
Table 10-12: BASF - Strengths and Weaknesses
Table 10-13: Royal DSM - Strengths and Weaknesses
Table 10-14: Divis Laboratories Limited - Strengths and Weaknesses
Table 10-15: Aurobindo Pharma Limited - Strengths and Weaknesses
Read the full report:
Global API Market Forecast to 2017
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article